News >

Immunotherapy May Have Place Among TKI Boom in EGFR+ NSCLC

Angelica Welch
Published: Thursday, Nov 29, 2018

Christine Bestvina, MD

Christine Bestvina, MD

Within the last decade, 4 tyrosine kinase inhibitors (TKIs) have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC). However, in recent years, both investigators and patients have been curious about the potential for immunotherapy. This should not underscore the successes of agents such as osimertinib (Tagrisso), though, said Christine Bestvina, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication